ACM Global appoints Asia Pacific general manager

He will initially build ACM Global team in India

ACM Global Central Laboratory has announced the newest member of its Clinical Trials team, Nandan Rao as general manager, Asia Pacific. He will be located in Mumbai, India and initially will have oversight of trials conducted with ACM Global’s partner lab in the region.

Rao will also be building the ACM Global infrastructure and team throughout Asia Pacific.

Rao was formerly general manager of SRL, the largest clinical reference laboratory network in India and Southeast Asia, where he built the firm’s clinical trials operations.

‘Since establishing its presence in India in 2006, ACM has become a global leader in the central lab arena,’ said Elena Logan, VP of Clinical Trials at ACM Global Central Lab.

‘Nandan’s expertise in building a central lab group in this region will be of significant value to our organisation as we continue to expand ACM Global wholly owned locations.’

You may also like

Regulatory

ACM Global relocates European hq to expanded lab facilities

Moves into a new, state-of-the-art facility in York, UK
Regulatory

ACM Global Central Laboratory establishes Mumbai subsidiary

Operational facility is dedicated to managing clinical trials testing in India and study support in Asia Pacific
Manufacturing

Gerresheimer adjusts 2025 guidance amid slower market growth

Transformation program launched to boost performance and free cash flow
Manufacturing

AstraZeneca strikes deal with US government to cut drug prices and boost domestic manufacturing

AstraZeneca has reached an agreement with the Trump administration to lower medicine costs, pledging $50bn in US manufacturing and R&D investment, whilst safeguarding the nation’s biopharma innovation leadership
Regulatory

A blueprint for Digital Health Medical Technologies (DHMTs)

Understanding compliance for digital mental health technologies
Finance

Bristol Myers Squibb strengthens and diversifies cell therapy portfolio with acquisition of Orbital Therapeutics

Bristol Myers Squibb will acquire Orbital Therapeutics in a $1.5bn deal, adding next-generation RNA-based in vivo CAR T technology to its cell therapy pipeline and expanding treatment potential in autoimmune diseases
Manufacturing

AstraZeneca to expand Virginia manufacturing facility with $4.5bn investment, creating 3600 jobs

AstraZeneca will develop a state-of-the-art manufacturing facility in Albemarle County, Virginia, producing a broader range of medicines, including weight management, metabolic and cancer therapies
Subscribe now